TC Biopharm (Holdings) Plc
TCBP · NASDAQ
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $939 | $1,299 | $1,847 | $1,847 |
| G&A Expenses | $1,115 | $2,143 | $1,430 | $1,430 |
| SG&A Expenses | $1,115 | $2,143 | $1,631 | $1,631 |
| Sales & Mktg Exp. | $0 | $0 | $201 | $201 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2,055 | $3,442 | $3,355 | $3,355 |
| Operating Income | -$2,055 | -$3,442 | -$3,277 | -$3,277 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$38 | $9 | -$3,719 | -$48 |
| Pre-Tax Income | -$2,092 | -$3,433 | -$3,325 | -$3,325 |
| Tax Expense | -$106 | -$111 | -$194 | -$194 |
| Net Income | -$1,987 | -$3,322 | -$3,130 | -$3,130 |
| % Margin | – | – | – | – |
| EPS | -0.3 | -1.4 | -3.36 | -3.36 |
| % Growth | 78.6% | 58.3% | 0% | – |
| EPS Diluted | -0.3 | -1.4 | -3.36 | -3.36 |
| Weighted Avg Shares Out | 6,491 | 3,014 | 933 | 933 |
| Weighted Avg Shares Out Dil | 6,491 | 3,014 | 933 | 933 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $30 | $30 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $121 | $127 | $144 | $144 |
| EBITDA | -$1,934 | -$3,315 | -$3,133 | -$3,133 |
| % Margin | – | – | – | – |